Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Please select


For My Business

< R10m annual turnover

For My Business

> R10m annual turnover

Switch to FNB Business

Product shop

By Turnover

First Business Zero (R0 - R5 million p.a) Gold Business (R0 - R5 million p.a) Platinum Business (R5 million - R60 million p.a) Enterprise Business (R60 million - R150 million+ p.a)

Transact

Business Accounts Credit Cards Cash Solutions Merchant Services eWallet Pro Staffing Solutions ATM Solutions Ways to bank Fleet Services Guarantees

Savings and Investments

Save and Invest 3PIM (3rd Party Investment Manager)

Borrow

FNB Cash Advance Overdraft Loans Debtor Finance Leveraged Finance Private Equity Securities Based Lending Selective Invoice Discounting Asset Based Finance Alternative Energy Solutions Commercial Property Finance Fleet Services

Insure

Insurance

For my employees

Staffing Solutions Employee benefits

Forex + Trade

Foreign Exchange Imports and exports Structured Trade + Commodity Finance Business Global Account (CFC account)

Value Adds + Rewards

Connect my business the dti initiatives Enterprise and supplier development Business Hub eBucks Rewards for Business DocTrail™ CIPC Integration Channel Instant Accounting Solutions Instant Payroll Instant Cashflow Instant Invoicing SLOW 24/7 Business Desk FNB Business Fundaba nav» Marketplace Prepaid products Accounting integrations

Industry Expertise

Philanthropy Chinese Business Islamic Banking Agriculture Public Sector Education Healthcare Franchise Motor Dealership Tourism

Going Global

Global Commercial Banking

Financial Planning

Overview

Bank Better

KYC / FICA Debit order + recipient switching Electronic Alerts

Corporates + Public Sector

Corporate Public Sector

All savings + investment accounts


Cash deposits

Notice deposits Immediate access Access to a portion Fixed deposits

Share investing

Shares

Tax-free investing

Tax-free accounts

Funds/unit trusts

Ashburton specialised products

Invest abroad

Offshore products

I want to save for

Personal goals Child's education Emergencies Tax-free

Compare similar

Compare

Additional options

Show me all Help me chosse Find an advisor

Financial planning

Overview

Back

Trade Ideas

Global Trade Idea: Align Technology (ALGN US) - BUY

 

By Peet Serfontein & Khumbulani Kunene

Align Technology is a global medical device company specialising in innovative solutions for orthodontics and restorative dentistry. Best known for its Invisalign clear aligner system, the company designs, manufactures, and markets its Invisalign product, which is a discreet, comfortable alternative to traditional braces. Align also provides advanced digital tools through its iTero intraoral scanners and exocad CAD/CAM software, empowering dental professionals to deliver precise, customised treatments.

To date, ~17 million people worldwide have been treated with the Invisalign System. The company operates in over 100 countries and is rapidly growing its international reach.

Technically, a price in a developing falling wedge pattern supports a promising investment opportunity (see the black converging trendlines on the main chart as well as the insert on the main chart). This pattern signals a reversal to an uptrend or a continuation of an existing bullish trend. A falling wedge forms when a stock's price consolidates between two downward-sloping trendlines, where the upper trendline (resistance) declines more steeply than the lower trendline (support). This represents a period of consolidation where selling pressure begins to diminish, which is seen with a slower pace of lower lows, indicating that bears are losing momentum, and bulls are taking control.

A consistent trend of outperformance in November reinforces a bullish outlook (see the insert). November, on average, returns +7.4%, a function of year-end optimism, seasonal market trends, and increased investor activity ahead of the holiday season. This momentum often carries into December (+2.7% return), supported by holiday spending.

Share Information
Share Code PG
Industry Health Care Equipment & Services
Market Capital (USD) 16.3 billion
One Year Total Return 0.60%
Return Year-to-Date -20.22%
Current Price (USD) 218.60
52 Week High (USD) 335.40
52 Week Low (USD) 196.09
Financial Year End December
The share price has fallen over the past year, but technical indicators support a potential near-term recovery.

Consensus Expectations (Bloomberg)
FY23 FY24E FY25E FY26E
Headline Earnings per Share (USD) 8.61 9.33 10.26 11.78
Growth (%) 8.41 9.96 14.77
Dividend Per Share (USD) 0.00 - - -
Growth (%) - - -
Forward PE (times) 21.50 18.82 18.56
Forward Dividend Yield (%) - - -
Earnings growth is expected to be decent in the short-to-medium term.

Buy/Sell Rationale:

Technical Analysis:

    • The lower panel shows the Bollinger Band Bandwidth indicator which measures the distance between the upper and lower Bollinger Bands. A low Bollinger Band bandwidth typically occurs during periods of price consolidation, where volatility decreases, and the stock trades within a narrow range. Consolidation often serves as a precursor to a significant price move and in a bullish case it suggests the stock is gathering momentum for an upward breakout.
    • The price remains below its 200-day simple moving average (SMA) of $259.81. This can be regarded as a bullish support under certain circumstances and can also signal oversold conditions.
    • The upward trajectory of the Coppock Curve supports a bullish case for the stock.
    • The recent steep upwards trajectory of the On-balance volume (OBV) indicator supports our view.
    • Our recommended entry range is $219 to $238, or as close as possible to $228.21 - a drop below this range would indicate a substantial change in price dynamics, giving reason to negate the trade idea.
    • Our target price is $275.00, representing ~20.5% upside from current levels.
    • Based on the forward calculation of the Relative Strength Index (RSI) indicator, the stock will be overbought at ~$335.00, making our profit target realistic.
    • Our proposed time to exit is mid-March 2025, but investors can adjust for an either longer or shorter time horizon, depending on price behaviour.
    • A drop below $210.00, -8.0% below current levels, would suggest weakening technicals and a stop-loss is recommended at this level.
    • We expect moderate fluctuations and therefore suggest a medium at-risk allocation for this trade. Increase exposure for a break above $238.00.

Fundamental view:

    • Align Technology operates through two segments that work synergistically, namely Clear Aligner and Systems & Services:
      • Clear Aligner (~80% of revenue) focuses on the design, manufacturing, and sale of the Invisalign system, which comprises of various products aimed at orthodontic treatments.
      • Imaging Systems and CAD/CAM Services (~20% of revenue) revolves around digital orthodontic and restorative solutions, mainly through iTero Intraoral scanners, Software and Services, and Exocad CAD/CAM dentistry solutions.
    • From a geographical perspective, ALGN generates ~45% of its revenue from the US, ~30% from Switzerland and ~25% from other countries.
    • The company has made several strategic acquisitions to enhance its capabilities in digital dentistry and orthodontics. In 2023, the company acquired Cubicure, which specialises in direct 3D printing and polymer additive manufacturing. In 2020 the company acquired Exocad, which is a leader in CAD/CAM software, and in 2011 they acquired Cadent, which specialises in 3D digital scanning and CAD/CAM solutions.
    • In 3Q24, the company's revenue increased by 1.8% y/y to $977.9 million with gains capped by unfavourable foreign exchange movements. Clear Aligner revenue dropped 1% y/y despite volumes increasing 2.5% y/y. Imaging Systems and CAD/CAM Services held the fort with revenue gaining 15.6% y/y.
    • Management remains focused on maximising shareholder value and has embarked on a restructuring journey. Management expects the restructuring action to be margin accretive in 2025, as the company scales its next generation direct 3D printing fabrication manufacturing.
    • From a risk perspective, the company remains exposed to operational risk, which includes supply chain vulnerabilities due to the company relying on complex manufacturing and global distribution networks. The is widely dependent on key suppliers such as manufacturing partners and material suppliers. Lastly, unfavourable economic conditions and foreign exchange fluctuations have shown to be detrimental to the company's performance.

Share Name and Position CHD US - Take profit
(Close the position)
DELL US - Buy
(Continue to hold)
CDE US - Buy
(Continue to hold)
Entry 104.14 123.78 6.23
Current 112.25 138.92 6.63
Movement 7.8% +12.2% +6.4%
The share price has performed well, and we suggest closing the trade to reduce portfolio exposure. A price in wave 5 of the Elliott wave price remains of interest. Remains above its 200-day SMA. Upside momentum is supportive.

Our profit target remains $148.00 with a trailing stop-loss at $127.00. Exit the trade by 10 January 2025.
A developing falling wedge pattern remains of interest. Remains above its 200-day simple moving average. Recent downside price momentum has halted.

Our profit target remains $8.00 with a trailing stop-loss at $5.80. Exit the trade by 10 January 2025.

Share Name and Position KMX US - Buy
(Continue to hold)
XLK US - Buy
(Continue to hold)
PG US - Buy
(Continue to hold)
Entry 76.44 230.09 170.76
Current 80.63 233.48 172.75
Movement +5.5% +1.5% +1.2%
A developing ascending triangle pattern remains of interest. Crossed above its 200-day simple moving average. Fading downside price momentum is supportive.

Our profit target remains at $90.00, with a trailing stop-loss at $75.40. Exit the trade by 31 January 2025.
A price in wave 5 of the Elliott wave analysis remains of interest. Remains above its 200-day simple moving average. Fading upside price momentum is a concern.

Our profit target remains at $256.00 with a trailing stop-loss at $223.00. Exit the trade by 24 January 2025.
An improving technical analysis score remains of interest. Remains above its 200-day SMA. Fading downside price momentum is supportive.

Our profit target remains at $185.00 with a trailing stop-loss at $167.50. Exit the trade by 19 February 2025.

FNB Stockbroking and Portfolio Management (Pty) Ltd, a subsidiary of FirstRand Bank Limited, an authorised Financial Services Provider and authorised user of the JSE limited (Reg no: 1996/011732/07). This Publication note is issued by FNB Stockbroking and Portfolio Management (Pty) Ltd for the information of clients only and should not be produced in whole or part without prior permission. Although FNB Stockbroking and Portfolio Management (Pty) Ltd is an Authorised Financial Services Provider, any opinions and/or analysis contained in this Publication are for informational purposes only and should not be considered advice, including but not limited to financial, legal or tax advice, or a recommendation to invest in any security or to adopt any investment strategy. The information contained herein has been obtained from sources/persons which we believe to be reliable but is not guaranteed for correctness, completeness or otherwise and we do not assume liability for loss arising from errors in the information or that may be suffered from using or relying on the information contained herein irrespective of whether there has been any negligence by us, our affiliates or any other employees of us, and whether such losses be direct or consequential. As market and economic conditions are subject to rapid change, any comments, opinions, and analysis is rendered as of the date of publishing and may change without notice. Such changes may have a material impact on the outcome of any investment. Securities involve a degree of risk and are volatile instruments. Past performance is not indicative of future performances. Securities or financial instruments mentioned in the Publication note may not be suitable for all investors and FNB Stockbroking and Portfolio Management (Pty) Ltd has bares no responsibility whatsoever arising from or as a consequence hereof. The material is not intended as a complete analysis of every material fact regarding any share, instrument, sector, region, market, country, investment, or strategy. The recipient of this Publication must make their own investment decision and is advised to contact his relationship manager for a personal financial analysis prior to making any investment decisions. Copyright 2018 by FNB Stockbroking and Portfolio Management (Pty) Ltd.